Drug intelligence / Profile preview

Shi-Er-Qing-Bi-Tang

Development stage: Preclinical
Lead developer: Beijing University of Chinese Medicine
Administration: Oral

Overview

Shi-Er-Qing-Bi-Tang is a Traditional Chinese Medicine (TCM) formula currently undergoing a multicenter clinical evaluation for its use in active rheumatoid arthritis. It is being studied in combination with Methotrexate tablets, with the aim of potentiating the effects of this Western medicine and reducing its associated toxicity. As a TCM formula, it is inherently a combination of multiple herbal ingredients, though its specific composition and detailed mechanism of action are not publicly detailed.

Beyond the preview

Go deeper on Shi-Er-Qing-Bi-Tang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shi-Er-Qing-Bi-Tang.

Explore the full profile